Related references
Note: Only part of the references are listed.2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease)
Mark A. Creager et al.
CIRCULATION (2012)
Nilotinib-Associated Vascular Events
Alfonso Quintas-Cardama et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
Susan Branford et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
Karl J. Aichberger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Thom W. Rooke et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Severe Peripheral Arterial Disease During Nilotinib Therapy
Philipp Le Coutre et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The Peripheral Arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population
Maria Teresa Alzamora et al.
BMC PUBLIC HEALTH (2010)
Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?
Stephen Fitter et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice
Nicole M Agostino et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Cardiotoxicity induced by tyrosine kinase inhibitors
George S. Orphanos et al.
ACTA ONCOLOGICA (2009)
Hypolipemiant besides antileukemic effect of imatinib mesylate
Radu Gologan et al.
LEUKEMIA RESEARCH (2009)
Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up
Claudia Lamina et al.
EUROPEAN HEART JOURNAL (2006)
ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) - A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery,* Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease)
AT Hirsch et al.
CIRCULATION (2006)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Imatinib attenuates diabetes-associated atherosclerosis
M Lassila et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling - Potential implications in atherosclerosis and lymphangioleiomyomatosis
N Ferri et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Prevalence of and risk factors for peripheral arterial disease in the United States - Results from the National Health and Nutrition Examination Survey, 1999-2000
E Selvin et al.
CIRCULATION (2004)
Share Paper
